临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 23288-49-5

Probucol

中文名称:丙丁酚
CAS号:23288-49-5
分子式: C31H48O2S2 分子量: 516.84
产品形式: free base
研发状态: Completed
研发用途: Dementia of the Alzheimer Type; Age-related Cognitive Decline; Mild Cognitive Impairment Due to Alzheimer Disease
研究机构: Douglas Mental Health University Institute; Weston Brain Institute; McGill University
研发日期: Apr-16
研发阶段: Phase 1 : Phase 2
Probucol (DH-581) is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.

CAS: 2326428-25-3

LY3405105

中文名称:1-哌啶羧酸,4-[[5-甲基-3-(1-甲基乙基)吡拉唑[1,5-a]嘧啶-7-基]氨基]-,1-[(2E)-4-(二甲基氨基)-1-氧基-2-丁烯-1-基]-3-吡咯里二基酯
CAS号:2326428-25-3
分子式: C26H39N7O3 分子量: 497.63
产品形式: Free Base
研发状态: Terminated
研发用途: Solid Tumor
研究机构: Eli Lilly and Company
研发日期: January 31 2019
研发阶段: Phase 1
LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.

CAS: 23261-20-3

Dianhydrogalactitol (VAL-083)

中文名称:1,2:5,6-二脱水半乳糖醇
CAS号:23261-20-3
分子式: C6H10O4 分子量: 146.14
产品形式: Free base
研发状态: Withdrawn
研发用途: Ovarian Cancer
研究机构: DelMar Pharmaceuticals Inc.; Kintara Therapeutics Inc.
研发日期: Mar-21
研发阶段: Phase 1 : Phase 2
Dianhydrogalactitol (VAL-083, Dianhydrodulcitol, Dulcitol Diepoxide) is a bi-functional alkylating agent that readily crosses the blood-brain barrier and creates N7 methylation on DNA. Dianhydrogalactitol shows antitumor activity.

CAS: 23256-50-0

Guanabenz Acetate

中文名称:乙酸胍那苄
CAS号:23256-50-0
分子式: C8H8Cl2N4.C2H4O2 分子量: 291.13
产品形式: Acetate
研发状态: Terminated
研发用途: Multiple Sclerosis Relapsing-Remitting; Multiple Sclerosis
研究机构: National Institute of Neurological Disorders and Stroke (NINDS); National Institutes of Health Clinical Center (CC)
研发日期: April 21 2015
研发阶段: Phase 1
Guanabenz Acetate (WY-8678) is an selective agonist of α2a-adrenergic receptor, α2b-adrenergic receptor and α2c-adrenergic receptor with pEC50 of 8.25, 7.01 and ~5, respectively.

CAS: 23239-51-2

Ritodrine HCl

中文名称:盐酸利托君
CAS号:23239-51-2
分子式: C17H21NO3.HCl 分子量: 323.81
产品形式: Hydrochloride
研发状态: Completed
研发用途: Healthy
研究机构: University Hospital Ghent
研发日期: May-08
研发阶段: Phase 1
Ritodrine HCl (NSC 291565,DU 21220, Ritodrine) is a hydrochloride salt of ritodrine which is a β-2 adrenergic receptor agonist.

CAS: 23180-57-6

Paeoniflorin (NSC 178886)

中文名称:芍药苷
CAS号:23180-57-6
分子式: C23H28O11 分子量: 480.46
产品形式: free base
研发状态: Not yet recruiting
研发用途: Ischemic Stroke Acute
研究机构: Ying Gao; Dongzhimen Hospital of Beijing University of Chinese Medicine Beijing; Dongzhimen Hospital Beijing
研发日期: September 25 2022
研发阶段: Phase 2 : Phase 3
Paeoniflorin (NSC 178886,Peoniflorin) is a herbal constituent extracted from the root of Paeonia albiflora Pall. Paeoniflorin reduces COX-2 expression. Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1α through mTOR-dependent pathway.